Astra Zeneca Covid Vaccine Trial Data: Thousands of Adverse Events, 621 Serious, Resulting in Death, Hospitalization, Disability

May 23rd, 2024

Via: The Counter Signal:

Data from AstraZeneca’s phase three trial results have recently become exposed, showing that within two years of receiving the shots, 1 in 3 participants reported suffering an adverse effect, and 1 in 35 experienced a “serious adverse event.”

Trial: A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19

More: AstraZeneca Gets £3 Billion Valuation Boost Following Global Vaccine Withdrawal

Leave a Reply

You must be logged in to post a comment.